Oral Therapy
Oral zasocitinib presents high potential as new psoriasis treatment
Zasocitinib, a potent and selective tyrosine kinase 2 inhibitor, safely and effectively cleared psoriasis in a high proportion of patients, according to a study.
KalVista Pharmaceuticals submits FDA application for sebetralstat
KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema, according to a company press release.
VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Raj Agrawal, MD, discusses the initial results of a phase 2a study of a novel therapy for patients with diabetic macular edema.
Phase 2 study of potential DME oral therapy meets primary endpoints
A phase 2 clinical study of RZ402, a potential oral therapy for diabetic macular edema, met its primary endpoints of safety and reduction in central subfield thickness, according to a press release from Rezolute.
Findings highlight ‘desperate need’ to improve end-of-life cancer treatment
Oncologic treatment of adults with various metastatic or advanced solid tumors may not improve OS and could be detrimental to quality of life, according to findings published in JAMA Oncology.
The Latest News and Notes, plus Conversation with Wiley A. Chambers, MD
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement.
Long-acting ART for HIV effective for people who struggle with daily pills
Results from an ongoing trial showed that long-acting injectable ART for HIV is effective for people who struggle to consistently take a daily course of medication, the NIH and ViiV Healthcare announced.
Top in ID: Efficacy of updated COVID-19 vaccines; challenges of delivering rural ID care
The updated COVID-19 vaccines were 54% effective against symptomatic SARS-CoV-2 infection and offered protection against JN.1 and XBB viral lineages, according to early estimates published by the CDC.
Oral therapy noninferior to IV for treating low-risk S. aureus bloodstream infections
Making an early switch to oral antibiotic therapy from IV therapy is safe and effective for patients with low-risk Staphylococcus aureus bloodstream infection, researchers determined.
First patient dosed in phase 1b/2a trial of oral danegaptide for diabetic retinopathy
Breye Therapeutics has begun dosing in its phase 1b/2a trial of oral danegaptide for treatment of diabetic macular edema, according to a company press release.